• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
AbdElrahman, A., Ahmed, M., Aboualy, O. (2022). COMPARISON BETWEEN GNRH AGONIST VERSUS DUAL TRIGGER INJECTION IN FREEZE ALL CYCLES FOR HIGH RESPONDER CASES. ALEXMED ePosters, 4(3), 5-6. doi: 10.21608/alexpo.2022.149467.1436
Ashraf Hany AbdElrahman; Mohamed Elmahdy Ahmed; Omar Ashraf Hassan Aboualy. "COMPARISON BETWEEN GNRH AGONIST VERSUS DUAL TRIGGER INJECTION IN FREEZE ALL CYCLES FOR HIGH RESPONDER CASES". ALEXMED ePosters, 4, 3, 2022, 5-6. doi: 10.21608/alexpo.2022.149467.1436
AbdElrahman, A., Ahmed, M., Aboualy, O. (2022). 'COMPARISON BETWEEN GNRH AGONIST VERSUS DUAL TRIGGER INJECTION IN FREEZE ALL CYCLES FOR HIGH RESPONDER CASES', ALEXMED ePosters, 4(3), pp. 5-6. doi: 10.21608/alexpo.2022.149467.1436
AbdElrahman, A., Ahmed, M., Aboualy, O. COMPARISON BETWEEN GNRH AGONIST VERSUS DUAL TRIGGER INJECTION IN FREEZE ALL CYCLES FOR HIGH RESPONDER CASES. ALEXMED ePosters, 2022; 4(3): 5-6. doi: 10.21608/alexpo.2022.149467.1436

COMPARISON BETWEEN GNRH AGONIST VERSUS DUAL TRIGGER INJECTION IN FREEZE ALL CYCLES FOR HIGH RESPONDER CASES

Article 3, Volume 4, Issue 3, September 2022, Page 5-6  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2022.149467.1436
View on SCiNiTO View on SCiNiTO
Authors
Ashraf Hany AbdElrahman1; Mohamed Elmahdy Ahmedorcid 2; Omar Ashraf Hassan Aboualy email 1
1Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University
2Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University, Egypt.
Abstract
Researchers tried different ovulatory triggers to replace HCG in high responders and PCOS patients as a trial to reduce the OHSS risk in such patients. In 1990 Gonen et al. proposed the use of the flare of the GnRH agonist trigger as a way to induce an endogenous LH and FSH surge mimicking normal physiology. At first studies found worse reproductive outcome due to defective luteal phase support cause by the short lived LH surge induced by the agonist trigger which failed to support early pregnancy.
Furthermore, the agonist trigger had a suboptimal response incidence around 5 %, this was specially observed in patients with low LH level at start of stimulation as patients with hypogonadotrophic hypogonadism and those who received combined oral contraceptives for a long period prior to stimulation. However, later studies proved that the GnRH agonist trigger alone or added to HCG has a positive effect on the embryological outcome of ICSI cycles. Similarly, multiple studies suggested positive effect of the dual trigger on oocyte and embryo quality.
Moreover, the dual trigger had a benefit in its ability to overcome the suboptimal response to the agonist trigger as well as possible benefit on the quality of oocytes and embryos.
The benefit of the dual trigger on the embryological and reproductive outcome in normal and poor responders in fresh cycles over hCG alone or agonist trigger alone was supported by many studies in recent literature.
Keywords
trigger; OHSS; agonist
Supplementary Files
download 1436 16.pdf
Statistics
Article View: 140
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.